Clinical Characteristics, Treatment, Diagnostic Findings, and Outcomes of Tuberculous Meningitis in Indonesia, 2022-2025 - NCT07929519

Sponsor: Ina-Respond Conditions: Tuberculous Meningitis TBM Study is a multicenter, observational, retrospective cohort study of Tuberculous Meningitis (TBM) patients who underwent treatment at the hospital during the 2022-2025 period. The goal of this study is to learn about the clinical characteristics, diagnostic findings, drug resistance profiles, treatment regimens, complications, and treatment outcomes of patients diagnosed with TBM who were admitted to the study hospitals between 2022 and 2025. This study uses retrospective data obtained from electronic medical records (EMR). Participants who admitted to the participating hospital sites between January 1, 2022, and December 31, 2025, have a discharge diagnosis of TBM (ICD-10 code A17.0) or documented TBM diagnosis in the hospital EMR system, and have accessible data available in the EMR will be enrolled to this study. The data will be collected at five timepoints: Timepoint 1: Hospital Admission Timepoint 2: TB Treatment Initiation Timepoint 3: Hospital Discharge Timepoint 4: End of Intensive Phase Timepoint 5: End of Treatment Six hospitals participate as the study sites. They are: 1. RS Penyakit Infeksi Prof. Dr. Sulianti Saroso (RSPI SS), Jakarta 2. RS Pusat Otak Nasional Prof. Dr. dr. Mahar Mardjono (RSPON), Jakarta 3. RSUP dr Mohammad Hoesin, Palembang 4. RSUP dr M Djamil, Padang 5. RSUP Prof Dr I.G.N.G. Ngoerah, Denpasar 6. RSUP dr Johannes Leimena, Maluku No biological specimens will be collected as part of the study. Data will be extracted from electronic medical records (EMR) at the study participating hospitals. Patient data will be collected from existing records at predefined time points through the end of treatment.